SG184724A1 - Methods, pharmaceutical compositions and articles of manufacture for administering therapeutic cells to the animal central nervous system - Google Patents

Methods, pharmaceutical compositions and articles of manufacture for administering therapeutic cells to the animal central nervous system Download PDF

Info

Publication number
SG184724A1
SG184724A1 SG2012066049A SG2012066049A SG184724A1 SG 184724 A1 SG184724 A1 SG 184724A1 SG 2012066049 A SG2012066049 A SG 2012066049A SG 2012066049 A SG2012066049 A SG 2012066049A SG 184724 A1 SG184724 A1 SG 184724A1
Authority
SG
Singapore
Prior art keywords
cells
therapeutic
pharmaceutical composition
cell
nasal cavity
Prior art date
Application number
SG2012066049A
Other languages
English (en)
Inventor
H Frey Ii William
Danielyan Lusine
H Gleiter Christoph
Original Assignee
H Frey Ii William
Danielyan Lusine
H Gleiter Christoph
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Frey Ii William, Danielyan Lusine, H Gleiter Christoph filed Critical H Frey Ii William
Publication of SG184724A1 publication Critical patent/SG184724A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
SG2012066049A 2007-09-11 2008-09-04 Methods, pharmaceutical compositions and articles of manufacture for administering therapeutic cells to the animal central nervous system SG184724A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97128407P 2007-09-11 2007-09-11
US12/109,066 US8283160B2 (en) 2007-09-11 2008-04-24 Methods, pharmaceutical compositions and articles of manufacture for administering therapeutic cells to the animal central nervous system

Publications (1)

Publication Number Publication Date
SG184724A1 true SG184724A1 (en) 2012-10-30

Family

ID=40432083

Family Applications (1)

Application Number Title Priority Date Filing Date
SG2012066049A SG184724A1 (en) 2007-09-11 2008-09-04 Methods, pharmaceutical compositions and articles of manufacture for administering therapeutic cells to the animal central nervous system

Country Status (24)

Country Link
US (3) US8283160B2 (cg-RX-API-DMAC7.html)
EP (1) EP2200621B1 (cg-RX-API-DMAC7.html)
JP (2) JP5600294B2 (cg-RX-API-DMAC7.html)
KR (2) KR20150039197A (cg-RX-API-DMAC7.html)
CN (2) CN101801397A (cg-RX-API-DMAC7.html)
AT (1) ATE554778T1 (cg-RX-API-DMAC7.html)
AU (1) AU2008299124B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0816325B8 (cg-RX-API-DMAC7.html)
CA (1) CA2696892C (cg-RX-API-DMAC7.html)
CR (1) CR11304A (cg-RX-API-DMAC7.html)
CY (1) CY1113120T1 (cg-RX-API-DMAC7.html)
DK (1) DK2200621T3 (cg-RX-API-DMAC7.html)
ES (1) ES2388403T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20120560T1 (cg-RX-API-DMAC7.html)
IL (1) IL204371A (cg-RX-API-DMAC7.html)
MX (1) MX2010002738A (cg-RX-API-DMAC7.html)
MY (1) MY154061A (cg-RX-API-DMAC7.html)
PL (1) PL2200621T3 (cg-RX-API-DMAC7.html)
PT (1) PT2200621E (cg-RX-API-DMAC7.html)
RU (1) RU2468818C2 (cg-RX-API-DMAC7.html)
SG (1) SG184724A1 (cg-RX-API-DMAC7.html)
SI (1) SI2200621T1 (cg-RX-API-DMAC7.html)
UA (1) UA98507C2 (cg-RX-API-DMAC7.html)
WO (1) WO2009035901A1 (cg-RX-API-DMAC7.html)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8518390B2 (en) * 2003-06-27 2013-08-27 Advanced Technologies And Regenerative Medicine, Llc Treatment of stroke and other acute neural degenerative disorders via intranasal administration of umbilical cord-derived cells
US8283160B2 (en) 2007-09-11 2012-10-09 Frey Ii William H Methods, pharmaceutical compositions and articles of manufacture for administering therapeutic cells to the animal central nervous system
EP2153844A1 (en) * 2008-08-14 2010-02-17 HAUBECK, Hans-Dieter Human hyaluronidases for axonal regrowth
NZ591292A (en) 2008-08-20 2012-10-26 Anthrogenesis Corp Improved cell composition and methods of making the same
US8609088B2 (en) 2011-05-10 2013-12-17 Regents Of The University Of Minnesota Intranasal delivery of therapeutic enzymes to the central nervous system for the treatment of lysosomal storage diseases
US10022083B2 (en) 2011-06-02 2018-07-17 Abdulmohsen E. A. H. Al-Terki Multiple oral and nasal surgical procedures method and kit
US8387798B1 (en) 2012-04-27 2013-03-05 Abdulmohsen E. A. H. Al-Terki Mutiple oral and nasal surgical procedures method and kit
US9821149B2 (en) * 2011-10-14 2017-11-21 Healthpartners Research & Education Methods for using ultrasound for enhancing efficiency and targeting of intranasal administration of therapeutic compounds to the central nervous system
KR101981450B1 (ko) 2011-12-23 2019-08-28 디퍼이 신테스 프로덕츠, 인코포레이티드 인간 제대 조직-유래된 세포의 검출
US20130336928A1 (en) * 2012-06-18 2013-12-19 Healthpartners Research & Education Methods and pharmaceutical compositions for treatment of central nervous system disorders with therapeutic agent(s) in patients with concurrent non-cns condition(s) or disorders contraindicating systemic administration of the therapeutic agent(s)
FR3001974B1 (fr) 2013-02-08 2016-02-12 Olivier Schussler Procede de purification de cellules
RU2522816C1 (ru) * 2013-02-12 2014-07-20 Российская Федерация, от имени которой выступает Министерство промышленности и торговли Российской Федерации (Минпромторг России) Композиция для клеточно-заместительной терапии дефектов мягких тканей
US10279012B2 (en) * 2013-03-11 2019-05-07 Healthpartners Research & Education Methods of treating and preventing social communication disorder in patients by intranasal administration of insulin
JP2016523835A (ja) 2013-05-15 2016-08-12 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 中枢神経系へのアデノ随伴ウイルスを介した遺伝子導入
US20170216286A1 (en) 2014-01-28 2017-08-03 Mayo Foundation For Medical Education And Research Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid
US9993472B2 (en) 2014-01-28 2018-06-12 Unity Biotechnology, Inc. Treatment for osteoarthritis in a joint by administering a means for inhibiting MDM2
CA2942172A1 (en) * 2014-03-06 2015-09-11 Children's National Medical Center Treatment of neonatal brain injury with hb-egf
KR102510426B1 (ko) * 2014-07-29 2023-03-15 피터 에덴호퍼 약의 전달을 위한 정압 호흡기 디바이스
US11413408B2 (en) 2014-07-29 2022-08-16 Peter Edenhoffer Positive pressure inspiration device for delivery of medicaments
US10130657B2 (en) 2015-02-13 2018-11-20 John C. Hughes Formulation, apparatus, and methods for treatment of brain trauma
US10335435B2 (en) 2015-05-22 2019-07-02 Marco Merida Method for endoscopically delivering stem cells to the brain using an intranasal, injectable approach
US20160361253A1 (en) * 2015-06-13 2016-12-15 Noveome Biotherapeutics, Inc. Novel Methods for Delivering Therapeutic Agents to the Eye via Nasal Passages
WO2017011326A1 (en) 2015-07-10 2017-01-19 Sanjay Gupta Nasal foam via cribriform plate for medication delivery to the brain and/or body and for nasal moisturization and hygiene
ES2938089T3 (es) * 2015-08-13 2023-04-04 Takeda Pharmaceuticals Co Tubos de extracción de sangre al vacío que contienen inhibidores de proteasa para la evaluación de la activación del sistema de contacto
US11253612B2 (en) 2016-04-15 2022-02-22 The Trustees Of The University Of Pennsylvania Gene therapy for treating mucopolysaccharidosis type II
CN106924286A (zh) * 2017-02-16 2017-07-07 上海安集协康生物技术股份有限公司 一种经鼻腔给药用于帕金森病治疗的神经干细胞制剂
CN108732355B (zh) * 2017-04-25 2021-06-25 首都医科大学附属北京安定医院 一种测定bace1酶切nrg1活性的检测方法及其试剂盒
US20190060109A1 (en) * 2017-08-31 2019-02-28 Gregory Todd Johnson Method of Preventing Traumatic Brain Injury (TBI)
EP3684938A1 (en) 2017-09-22 2020-07-29 The Trustees of the University of Pennsylvania Gene therapy for treating mucopolysaccharidosis type ii
CN108096280A (zh) * 2017-12-28 2018-06-01 上海安集协康生物技术股份有限公司 一种神经干细胞滴鼻剂
KR20220005900A (ko) * 2020-07-07 2022-01-14 가톨릭대학교 산학협력단 뇌신경계질환 예방 또는 치료용 약학적 조성물

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5624898A (en) * 1989-12-05 1997-04-29 Ramsey Foundation Method for administering neurologic agents to the brain
US20040266715A1 (en) * 1999-03-31 2004-12-30 Wong Liang Fong Neurite regeneration
US6667176B1 (en) * 2000-01-11 2003-12-23 Geron Corporation cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells
WO2000033813A1 (en) * 1998-12-09 2000-06-15 Chiron Corporation Administration of neurotrophic agents to the central nervous system
ATE407695T1 (de) * 1999-02-09 2008-09-15 Riken Tumorimpfstoff
US6749850B1 (en) * 1999-08-18 2004-06-15 The General Hospital Corporation Methods, compositions and kits for promoting recovery from damage to the central nervous system
US20020169102A1 (en) * 2001-04-03 2002-11-14 Frey William H. Intranasal delivery of agents for regulating development of implanted cells in the CNS
JP3886346B2 (ja) * 2001-06-22 2007-02-28 サンバイオ,インコーポレイティド 骨髄間質細胞由来Schwann細胞を含む神経再生用医薬組成物
EP1438942A1 (en) 2003-01-17 2004-07-21 Schering Oy An otorhinological drug delivery device
EP1709151B1 (en) * 2003-12-02 2016-04-13 Celavie Biosciences, LLC Compositions and methods for propagation of neural progenitor cells
WO2007002664A2 (en) * 2005-06-22 2007-01-04 Massachusetts Institute Of Technology Propagation of undifferentiated embryonic stem cells in hyaluronic acid hydrogel
US9456979B2 (en) * 2006-04-27 2016-10-04 Sri International Adminstration of intact mammalian cells to the brain by the intranasal route
US8168169B2 (en) * 2006-08-09 2012-05-01 Mclean Hospital Corporation Methods and compositions for the treatment of medical disorders
US8283160B2 (en) 2007-09-11 2012-10-09 Frey Ii William H Methods, pharmaceutical compositions and articles of manufacture for administering therapeutic cells to the animal central nervous system

Also Published As

Publication number Publication date
KR20100094450A (ko) 2010-08-26
EP2200621A4 (en) 2011-03-16
RU2468818C2 (ru) 2012-12-10
ES2388403T3 (es) 2012-10-15
UA98507C2 (ru) 2012-05-25
JP5600294B2 (ja) 2014-10-01
WO2009035901A1 (en) 2009-03-19
US20090068155A1 (en) 2009-03-12
US20130028874A1 (en) 2013-01-31
CN101801397A (zh) 2010-08-11
JP2010539084A (ja) 2010-12-16
MX2010002738A (es) 2010-08-04
RU2010113932A (ru) 2011-10-20
EP2200621A1 (en) 2010-06-30
CA2696892C (en) 2016-05-17
PT2200621E (pt) 2012-07-31
CR11304A (es) 2010-05-03
PL2200621T3 (pl) 2012-10-31
KR20150039197A (ko) 2015-04-09
ATE554778T1 (de) 2012-05-15
US9445991B2 (en) 2016-09-20
DK2200621T3 (da) 2012-08-06
MY154061A (en) 2015-04-30
BRPI0816325B8 (pt) 2021-05-25
AU2008299124B2 (en) 2013-07-04
BRPI0816325B1 (pt) 2020-04-22
US8283160B2 (en) 2012-10-09
HRP20120560T1 (hr) 2012-08-31
CN103181932A (zh) 2013-07-03
US20160206554A1 (en) 2016-07-21
BRPI0816325A2 (pt) 2015-03-24
IL204371A (en) 2015-02-26
CY1113120T1 (el) 2016-04-13
EP2200621B1 (en) 2012-04-25
SI2200621T1 (sl) 2012-09-28
JP2014098051A (ja) 2014-05-29
KR101504110B1 (ko) 2015-03-19
CA2696892A1 (en) 2009-03-19
AU2008299124A1 (en) 2009-03-19

Similar Documents

Publication Publication Date Title
US9445991B2 (en) Methods, pharmaceutical compositions and articles of manufacture for administering therapeutic cells to the animal central nervous system
JP2010539084A5 (cg-RX-API-DMAC7.html)
US20020169102A1 (en) Intranasal delivery of agents for regulating development of implanted cells in the CNS
CN101410126A (zh) 无附加的免疫抑制治疗的mapc治疗法
JPWO2002002135A1 (ja) 脱髄疾患の予防及び治療薬
JP2015025018A (ja) 神経変性障害
CN107148275A (zh) 包含编码生长因子的外源多核苷酸的稳定的神经干细胞及其使用方法
CN103028110B (zh) 抗分泌因子的新用途
US20200085735A1 (en) Novel methods for delivering therapeutics agents to the eye via the nasal passages
US20240012011A1 (en) Methods and assays for secretome activity analysis
US9636364B2 (en) Methods for treating ocular contusion and blunt injury and traumatic injury to the optic nerve
Shamaa et al. A review: Multiple Sclerosis Treatment: Current Strategies and Future Hopes.
US20230134557A1 (en) Pharmaceutical composition comprising stem cell-conditioned medium and exosome isolated therefrom as active ingredient for prevention or treatment of ocular disease
HK1182932A (en) Methods, pharmaceutical compositions and articles of manufacture for administering therapeutic cells to the animal central nervous system
US20240091268A1 (en) Preparation and purification methods for mesenchymal stem cell derived secretome
WO2004105787A1 (en) Methods of using combinations of egf-2 and egf-20 to treat central nervous system disorders
US20160296606A1 (en) Cellular Factor-Containing Solution Compositions for the Treatment of Rhinovirus Infection and Symptoms
WO2010060928A2 (en) Compositions for the treatment of ischemic tissue damage